HC Wainwright Forecasts Increased Earnings for Nanobiotix

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) – Analysts at HC Wainwright boosted their FY2030 earnings per share estimates for Nanobiotix in a research report issued on Monday, May 18th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $2.95 per share for the year, up from their previous forecast of $2.65. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Nanobiotix’s current full-year earnings is $0.53 per share.

Nanobiotix (NASDAQ:NBTX) last announced its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $3.42 million during the quarter.

Several other equities analysts also recently commented on the company. UBS Group boosted their price objective on Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Guggenheim boosted their price objective on Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, April 2nd. TD Cowen restated a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Nanobiotix has a consensus rating of “Moderate Buy” and an average target price of $26.67.

Nanobiotix Stock Performance

Shares of Nanobiotix stock opened at $49.48 on Tuesday. The stock’s 50-day simple moving average is $35.36 and its 200-day simple moving average is $27.04. Nanobiotix has a 52 week low of $3.64 and a 52 week high of $57.14.

Institutional Investors Weigh In On Nanobiotix

Large investors have recently made changes to their positions in the company. Royal Bank of Canada increased its holdings in shares of Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares during the last quarter. Optiver Holding B.V. bought a new stake in Nanobiotix during the third quarter worth approximately $101,000. Marshall Wace LLP bought a new stake in Nanobiotix during the fourth quarter worth approximately $220,000. Finally, Millennium Management LLC bought a new stake in Nanobiotix during the fourth quarter worth approximately $390,000. 38.81% of the stock is owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.